Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective.
作者信息
Lieberman Jeffrey A
机构信息
Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY, USA.
出版信息
World Psychiatry. 2018 Jun;17(2):163-165. doi: 10.1002/wps.20543.
Abstract
摘要
相似文献
1
Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective.抗精神病药物对精神分裂症的疾病修饰作用：临床与神经生物学视角
World Psychiatry. 2018 Jun;17(2):163-165. doi: 10.1002/wps.20543.
2
Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective.精神分裂症的大脑结构变化与抗精神病药物有关吗？从临床角度对证据的叙述性综述。
Ther Adv Psychopharmacol. 2018 Jun 15;8(11):319-326. doi: 10.1177/2045125318782306. eCollection 2018 Nov.
3
Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?非典型抗精神病药物是否能改善精神分裂症的长期病程？
J Psychiatr Res. 1998 May-Aug;32(3-4):229-42. doi: 10.1016/s0022-3956(98)00024-7.
4
Can antipsychotic treatment contribute to drug addiction in schizophrenia?抗精神病药物治疗会导致精神分裂症患者药物成瘾吗？
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:9-16. doi: 10.1016/j.pnpbp.2013.06.008. Epub 2013 Jun 20.
5
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?谷氨酸能抗精神病药物：精神分裂症治疗的新曙光？
Ther Adv Psychopharmacol. 2011 Feb;1(1):5-18. doi: 10.1177/2045125311400779.
6
Assessment of electroencephalography modification by antipsychotic drugs in patients with schizophrenia spectrum disorders using frontier orbital theory: A preliminary study.采用前沿轨道理论评估抗精神病药物对精神分裂症谱系障碍患者脑电图的修饰：一项初步研究。
Neuropsychopharmacol Rep. 2023 Jun;43(2):177-187. doi: 10.1002/npr2.12318. Epub 2023 Feb 22.
7
Safety of antipsychotic drugs: focus on therapeutic and adverse effects.抗精神病药物的安全性：关注治疗效果和不良反应。
Expert Opin Drug Saf. 2014 Aug;13(8):1031-42. doi: 10.1517/14740338.2014.935761. Epub 2014 Jun 30.
8
Developing therapeutics for schizophrenia and other psychotic disorders.开发针对精神分裂症和其他精神障碍的治疗方法。
NeuroRx. 2005 Oct;2(4):579-89. doi: 10.1602/neurorx.2.4.579.
9
Development of disease-modifying treatment of schizophrenia.精神分裂症疾病修饰治疗的进展
Handb Exp Pharmacol. 2012(213):419-42. doi: 10.1007/978-3-642-25758-2_14.
10
[Neurobiological and pharmacologic aspects of atypical antipsychotic drugs].非典型抗精神病药物的神经生物学和药理学方面
Orv Hetil. 2009 Aug 16;150(33):1539-44. doi: 10.1556/OH.2009.28660.
引用本文的文献
1
Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.精神分裂症的神经退行性模型：越来越多的证据支持重新审视。
Schizophr Res. 2022 May;243:154-162. doi: 10.1016/j.schres.2022.03.004. Epub 2022 Mar 25.
2
Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis.维持期抗精神病药物最小有效剂量的挑战：首发精神病10年随访的启示
Front Psychiatry. 2021 Sep 7;12:714878. doi: 10.3389/fpsyt.2021.714878. eCollection 2021.
3
Application value of UPLC-MS/MS in detecting serum concentration of anti-schizophrenic drugs in patients with mental illnes.超高效液相色谱-串联质谱法在检测精神病患者抗精神分裂症药物血清浓度中的应用价值
Am J Transl Res. 2021 May 15;13(5):5460-5467. eCollection 2021.
4
Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function.奥氮平联合利培酮治疗精神分裂症的疗效及其对认知功能的影响。
Pak J Med Sci. 2021 May-Jun;37(3):646-650. doi: 10.12669/pjms.37.3.3348.
本文引用的文献
1
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?精神分裂症患者长期使用抗精神病药物治疗的风险效益比是多少？
World Psychiatry. 2018 Jun;17(2):149-160. doi: 10.1002/wps.20516.
2
Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis.未治疗精神病持续时间对精神分裂症长期结局的预测作用：系统评价和荟萃分析。
Br J Psychiatry. 2014 Aug;205(2):88-94. doi: 10.1192/bjp.bp.113.127753. Epub 2014 Aug 1.
3
Changes in cortical thickness during the course of illness in schizophrenia.精神分裂症病程中皮质厚度的变化。
Arch Gen Psychiatry. 2011 Sep;68(9):871-80. doi: 10.1001/archgenpsychiatry.2011.88.
4
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.抗精神病药物对慢性精神分裂症患者的疗效。
N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.
5
The natural course of schizophrenia and effective maintenance drug treatment.精神分裂症的自然病程与有效的维持性药物治疗
J Clin Psychopharmacol. 1986 Feb;6(1 Suppl):2S-10S.
6
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.接受恩卡尼、氟卡尼或安慰剂治疗患者的死亡率和发病率。心律失常抑制试验。
N Engl J Med. 1991 Mar 21;324(12):781-8. doi: 10.1056/NEJM199103213241201.
7
Neuroleptics and the natural course of schizophrenia.抗精神病药物与精神分裂症的自然病程
Schizophr Bull. 1991;17(2):325-51. doi: 10.1093/schbul/17.2.325.
Zotero 插件